Bayer, a German brand that makes many pharmaceutical drugs, health products, and farming products, has agreed to settle claims that their weedkiller brand, Round-Up, failed to inform the public that their were chemical agents that could cause cancer on the 17th of February.

Bayer’s Chief Executive Officer, Bill Anderson, bought Monsanto, the maker of Round-Up, 8 years ago for $63 billion. The International Agency for Research on Cancer found, in 2015, that the weedkiller contained chemicals that would make it a human carcinogen although, Bayer and others, including the U.S. Environmental Protection Agency, disagreed with those findings. It has still caused multiple years of litigation in the U.S.

According to the terms of settlement, which Bayer says they have finished over 130,000 claims so far, anyone who was exposed to Round-Up before February 17th of this year that was diagnosed with non-Hodgkin Lymphoma within 16 years is eligible.

Attorney Christian Seeger, who represents those who benefit from claims, said that “No settlement can erase a diagnosis, but this agreement is designed to ensure that both today’s and tomorrow’s patients have access to meaningful compensation”(Lieb,Feb 17).

Anderson expected that people with pending claims will sign onto the new settlement stating that “This doesn’t work unless there is closure”(Sherman,Feb 17). Bayer has stated that the payments would be made out over the course of a 21 year period with a majority of its payouts being made within the first five years. The company says it also expects to pay three billion in other Round-Up cases, including with several states over its relation with forever chemicals.